REGULATION OF HUMORAL IMMUNITY BY COMPLEMENT RECEPTORS
补体受体对体液免疫的调节
基本信息
- 批准号:6373575
- 负责人:
- 金额:$ 25.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-07-01 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Many of the immunological effects attributed to the third
component of complement (C3) are mediated by specific cell
membrane complement receptors. Complement receptor 1 (CR1)
is the immune adherence receptor and participates in C3b-
dependent phagocytosis, lymphocyte function and the regulation of
C3 activation. Complement receptor 2 (CR2) is involved in
lymphocyte activation, in the primary immune response to
antigens and in the generation of immunological memory. In
some rheumatologic disorders, such as SLE , the levels of these
receptors are abnormal, suggesting a role in the pathophysiology
of the disease. CR1/CR2 deficient mice have been developed
using gene targeting techniques. These mice are unable to mount
a normal humoral immune response to specific antigen
stimulation. Since mouse CR1 and 2 are the alternatively spliced
product of the same gene, the CR1/CR2 deficient mice lack
expression of both proteins. However, previous studies have
indicated unique functions for each protein. The relative
contributions of CR1 versus CR2 to the immune abnormalities
observed in the receptor deficient mice, therefore, are not yet
defined. We propose to selectively reconstitute each of these
proteins in our CR1/CR2 deficient mice using tansgenic
technology. Constructs will be designed containing cDNAs
encoding each specific complement receptor under the kappa light
chain promoter/enhancer transcriptional control, which will direct
receptor expression to B lymphocytes. Other promoters will be
considered based on their ability to direct tissue specific
expression of these receptors. These constructs will be injected
individually to generate transgenic mice that express only one of
these receptors. Following backcrossing into CR1/CR2 deficient
mice, the immune response to different antigens will then be
evaluated. These experiments will clarify the different roles of
these proteins in the immune response.
许多免疫效应归因于第三种
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HECTOR D MOLINA其他文献
HECTOR D MOLINA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HECTOR D MOLINA', 18)}}的其他基金
REGULATION OF HUMORAL IMMUNITY BY COMPLEMENT RECEPTORS
补体受体对体液免疫的调节
- 批准号:
2887335 - 财政年份:1997
- 资助金额:
$ 25.38万 - 项目类别:
REGULATION OF HUMORAL IMMUNITY BY COMPLEMENT RECEPTORS
补体受体对体液免疫的调节
- 批准号:
2672894 - 财政年份:1997
- 资助金额:
$ 25.38万 - 项目类别:
REGULATION OF HUMORAL IMMUNITY BY COMPLEMENT RECEPTORS
补体受体对体液免疫的调节
- 批准号:
6170077 - 财政年份:1997
- 资助金额:
$ 25.38万 - 项目类别:
REGULATION OF HUMORAL IMMUNITY BY COMPLEMENT RECEPTORS
补体受体对体液免疫的调节
- 批准号:
2595876 - 财政年份:1997
- 资助金额:
$ 25.38万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 25.38万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 25.38万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 25.38万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 25.38万 - 项目类别:
Discovery Grants Program - Individual